In an era where venture capital flows like molasses—particularly for fledgling spine startups navigating regulatory hurdles, market saturation, and investor skepticism—how does a company like PainTEQ, peddling what many might dismiss as "me-too" products in the overcrowded sacroiliac fusion space, secure a whopping $35 million in fresh equity amid 2025's notoriously stingy financial climate?
Could the secret sauce lie in the credibility of physician-led innovation, where MD founders or advisors lend an aura of clinical authority that turns heads in boardrooms, or is it simply a testament to m...
